Stem cell infusion for hard-to-treat lupus kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether infusing special stem cells (called mesenchymal stem cells) can help treat lupus nephritis that hasn't responded to standard therapy. It aims to calm the immune system and reduce kidney inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lupus (SLE) and active lupus nephritis (kidney inflammation from lupus).
- Your kidney disease has not gotten better after 6 to 12 months of standard lupus treatments.
- You do not have severe kidney or liver damage, and your kidney function (eGFR) is above 45.
- You are not pregnant, breastfeeding, and agree to use effective birth control during the study and for 12 months after.
- You do not have any other autoimmune diseases like rheumatoid arthritis or scleroderma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target two proteins (CD19 and BCMA) on lupus cells. It is for people with lupus nephritis (kidney inflammation) that has not improved after trying multiple standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.